Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Nutr Metab Cardiovasc Dis
; 33(7): 1444-1452, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-37246074
ABSTRACT
BACKGROUND AND AIMS:
Recently, pemafibrate, a selective PPARα modulator, has been developed as a treatment for hypertriglyceridemia and has attracted much attention. The aims of this study were to evaluate the efficacy and safety of pemafibrate in hypertriglyceridemia patients under clinical settings. METHODS ANDRESULTS:
We evaluated changes in lipid profiles and various parameters before and after 24-week pemafibrate administration in patients with hypertriglyceridemia who had not previously taken fibrate medications. There were 79 cases included in the analysis. 24 weeks after the treatment with pemafibrate, TG was significantly reduced from 312 ± 226 to 167 ± 94 mg/dL. In addition, lipoprotein fractionation tests using PAGE method showed a significant decrease in the ratio of VLDL and remnant fractionations, which are TG-rich lipoproteins. After pemafibrate administration, body weight, HbA1c, eGFR, and CK levels were not changed, but liver injury indices such as ALT, AST, and γ-GTP were significantly improved.CONCLUSION:
In this study, pemafibrate improved the metabolism of atherosclerosis-induced lipoproteins in hypertriglyceridemia patients. In addition, it showed no off-target effects such as hepatic and renal damage or rhabdomyolysis.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Hipertrigliceridemia
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article